ライフサイエンスコーパス: SBP

1 SBP and HR were significantly decreased compared with th

2 SBP reduction was strongly associated with worsening ren

3 SBP reductions in adults with the highest levels of SBP

4 SBP was continuously related to the risk of mitral regur

5 .29; -0.13), FBG -2.40 mg/dL (-3.59; -1.21), SBP -4.29 mmHg (-5.73, -2.84), DBP -2.56 mmHg (-3.40, 1.

6 This LCGM method identified 5 SBP trajectories and association analyses identified a g

7 timated 10-year number-needed-to-treat for a SBP goal of 120mmHg varied substantially according to CA

8 eligibility criteria and may benefit from a SBP target goal of 120 mm Hg.

9 Intervention Trial (SPRINT) suggested that a SBP level of lower than 120 mm Hg decreases cardiovascul

10 lume, greater ICH growth and higher achieved SBP over 24 h.

11 INTERPRETATION: Mean achieved SBP less than 120 mm Hg during treatment was associated

12 Mean achieved SBP more accurately predicted outcomes than baseline or

13 In young adulthood, SBP in black individuals and DBP in white individuals we

14 In middle-age, SBP in both races identified risk of incident CVD.

15 lity (SBPV) was measured using the SD of all SBP values (normally distributed) in 1 individual.

16 supplementation also lowered 24-h ambulatory SBP and DBP.

17 mm Hg or greater, and a mean 24-h ambulatory SBP of 140 mm Hg or greater and less than 170 mm Hg at s

18 se with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, resp

19 d and 19.8 million treated US adults have an SBP in the diagnostic and treatment gray zone (120-139 m

20 t, participants were classified as having an SBP level of 120 mm Hg or lower, 121 to 139 mm Hg, 140 t

21 ion in infancy reduced the odds of having an SBP within the hypertensive range at 7 y of age (OR: 0.3

22 hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140 mm Hg reduced rates of

23 dults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBP t

24 Particularly among adults with an SBP >/=120 mm Hg, and thus elevated pulse pressure, low

25 ommendations were extended to adults with an SBP between 120 and 139 mm Hg, as well as prior CVD or C

26 vascular disease (CVD) risk compared with an SBP goal of <140 mm Hg.

27 rget of less than 120 mm Hg compared with an SBP target of less than 140 mm Hg resulted in significan

28 AC levels when predicted ASCVD risk <15% and SBP <160mmHg (eg, 10-year number-needed-to-treat of 99 f

29 n association between gammadelta T cells and SBP.

30 Simultaneous EMG and SBP were acquired from elderly group (69 +/- 4 years, n

31 cate that the impact of increasing HbA1c and SBP on DR probability is incrementally the same in both

32 identical DR probability based on HbA1c and SBP.

33 We used Cox regression to compare HE and SBP rates between users and nonusers of PPIs.

34 rane, suggesting a synergy between HELLP and SBP in membrane dismantling.

35 d the risk of dementia in relation to OH and SBP variability, using a Cox regression model, adjusted

36 9 mm Hg or when ASCVD risk was >/=15% at any SBP level.

37 centage of incident CVD events that occur at SBP/DBP <140/90 mm Hg in a pooled analysis of 3 contempo

38 of zinc binding and release among bacterial SBPs are of considerable interest as antibacterial drug

39 Mean baseline SBP and DBP were 139.7+/-15.6 and 78.1+/-11.9 mm Hg, res

40 ater reductions at higher levels of baseline SBP.

41 d -7.04 mm Hg across the respective baseline SBP strata listed (p for trend = 0.004).

42 most pronounced among patients with baseline SBP >/=120 mm Hg.

43 In humans, the association between SBP and gammadelta T cells was demonstrated by a multipl

44 effect on the long-term association between SBP and mitral regurgitation (mediator-adjusted HR 1.22;

45 y contrast, there was no association between SBP and risk of mitral stenosis (HR per 20 mmHg higher S

46 There was no adjusted association between SBP hypotension < 80 mm Hg and SSI, with an estimated od

47 Both SBP and DBP were positively associated with BMI, WC, and

48 Within subgroups categorized by both SBP (120-139 mm Hg, 140-159 mm Hg, and 160-179 mm Hg) an

49 ad a significantly greater reduction in both SBP (SMD: -0.20; 95% CI: -0.37, -0.03) and DBP (SMD: -0.

50 dels, each 1-mm Hg increment in systolic BP (SBP) was associated with 0.8% (95% confidence interval [

51 mbulatory hypertension (daytime systolic BP [SBP]/diastolic BP [DBP] >/=135/85 mm Hg, 24-hour SBP/DBP

52 nd BP-II respond similarly to treatment, but SBP patients may have different neuroinflammation marker

53 ed LV wall active tension when normalized by SBP.

54 lesterol, triglycerides, TC:HDL cholesterol, SBP, and DBP, respectively].

55 and nighttime SBP corresponding to a clinic SBP >/=140 mm Hg were 138 mm Hg, 134 mm Hg, and 129 mm H

56 ghttime hypertension corresponding to clinic SBP/DBP >/=140/90 mm Hg are proposed for African America

57 nd nighttime SBP/DBP corresponding to clinic SBP/DBP of 140/90 mm Hg were 134/85 mm Hg, 130/81 mm Hg,

58 nd nighttime SBP/DBP corresponding to clinic SBP/DBP of 140/90 mm Hg were 135/85 mm Hg, 133/82 mm Hg,

59 o intensive (SBP<120 mm Hg) or conventional (SBP<140 mm Hg) treatment were pooled and harmonized for

60 Patients with low 30-day SBP and high pulsatile load had a 3-fold higher mortalit

61 higher mortality than those with high 30-day SBP and low pulsatile load (26.1% versus 8.1%; hazard ra

62 roposed for African American adults: daytime SBP/DBP >/=140/85 mm Hg, 24-hour SBP/DBP >/=135/80 mm Hg

63 During the follow-up, 86 patients developed SBP.

64 ortality in patients randomized to different SBP targets.

65 The association of these discordant SBP targets with cognition and differences by race have

66 To release the stable docked SBP from the transporter hydrolysis of ATP is required.

67 studies, we found that genetically elevated SBP was associated with increased risk for type 2 diabet

68 evaluate the causal hypothesis that elevated SBP increases risk for type 2 diabetes.

69 , was significantly associated with elevated SBP, DBP, and cPP, and with lower FMD, adjusting for age

70 rofiles of various populations with elevated SBP.

71 Conserved genome neighborhoods encoded SBPs as well as permease components of the TRAP transpor

72 associated with higher mortality (20.0% for SBP 100-129 mm Hg versus 12.0% for SBP 130-170 mm Hg; P<

73 20.0% for SBP 100-129 mm Hg versus 12.0% for SBP 130-170 mm Hg; P<0.001).

74 he basis of the outcome-derived approach for SBP and regression-derived approach for DBP, the followi

75 e was no significant intervention effect for SBP; a significant difference for DBP (P = 0.031) existe

76 its reduced the overall pooled estimates for SBP and DBP by 1.1 mm Hg (95% CI: -0.3, 2.5 mm Hg; P = 0

77 its reduced the overall pooled estimates for SBP and DBP by 2.0 mm Hg (95% CI: 0.2, 3.8 mm Hg; P = 0.

78 steine, the coefficients were -1.8 mm Hg for SBP (95% CI: -3.9, 0.4 mm Hg; P = 0.01) and 0.1 mm Hg fo

79 oach, BP thresholds were identified only for SBP because clinic DBP was not associated with the outco

80 A significant (p = 0.002) decline in EMG --> SBP causality was observed in the elderly group, compare

81 und to drive blood pressure control (EMG --> SBP) as well as control the postural sway (EMG --> COPr)

82 and 24-h blood pressure from baseline: 24-h SBP -5.0 mm Hg (95% CI -9.9 to -0.2; p=0.0414), 24-h DBP

83 <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressur

84 (<140 mm Hg) or guideline-based (<180 mm Hg) SBP management.

85 Clusters of metabolic factors (high SBP, high BMI, high fasting plasma glucose, high total c

86 characteristics (lower baseline eGFR, higher SBP and diastolic BP), and comorbidities (presence of di

87 Post hoc analysis showed that KOM had higher SBP than KOP (P < 0.05).

88 sk of mitral stenosis (HR per 20 mmHg higher SBP 1.03; CI 0.93, 1.14; p = 0.58).

89 POL1 risk alleles are associated with higher SBP and earlier hypertension diagnoses in young AAs; thi

90 VA was significantly associated with higher SBP and PP in males.

91 /diastolic BP [DBP] >/=135/85 mm Hg, 24-hour SBP/DBP >/=130/80 mm Hg, and nighttime SBP/DBP >/=120/70

92 ts: daytime SBP/DBP >/=140/85 mm Hg, 24-hour SBP/DBP >/=135/80 mm Hg, and nighttime SBP/DBP >/=130/75

93 However, SBP reduction did not negatively affect diuresis or deco

94 6.4% of control subjects were hypertensive (SBP >/=140 and/or DBP >/=90 mm Hg) versus 1.9% of ethano

95 Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indistinguishab

96 ative mass spectrometry was used to identify SBP-AR and associated ligand-sensitive cytosolic protein

97 tion of adhesion molecules and a decrease in SBP and DBP.

98 etes risk per 1 mmHg of genetic elevation in SBP (odds ratio 1.02, 95% CI 1.01-1.03, P = 1.48 x 10(-3

99 causal role in blood pressure, especially in SBP.

100 esulted in a mean reduction of 4.18 mm Hg in SBP and 2.27 mm Hg in DBP.The pooled results suggest tha

101 increase of 0.9 (95% CI: 0.4, 1.4) mm Hg in SBP and of 1.0 (95% CI: 0.6, 1.4) mm Hg in DBP.

102 8-mmHg (95% CI: 1.45, 3.50 mmHg) increase in SBP and 2.22-mmHg (95% CI: 1.69, 2.75 mmHg) increase in

103 f 0.97 (0.81, 1.17) per 5-minute increase in SBP hypotension (P = 0.54).

104 - to 29-year age range showed an increase in SBP of 0.94 +/- 0.44 mm Hg (pcom = 0.01) per risk varian

105 Each 20 mmHg increment in SBP was associated with a 26% higher risk of mitral regu

106 calculated within participant variability in SBP related to postural change, expressed as coefficient

107 In adjusted models that included SBP, higher total and pulsatile arterial load were assoc

108 m Cox proportional hazards models, including SBP and DBP, jointly suggested that, at Y0, SBP (hazard

109 Fourteen days of Ang II infusion increased SBP (P<0.01) and decreased mesenteric artery endothelial

110 ISA, and NTL were associated with increased SBP, DBP, and cPP, and with reduced FMD, suggesting a po

111 seline eGFR, comorbidities, body mass index, SBP, diastolic BP, and antihypertensive medication use.

112 gammadelta T cells mediate Ang II-induced SBP elevation, vascular injury, and T-cell activation in

113 elta T-cell depletion blunted Ang II-induced SBP rise and endothelial dysfunction (P<0.05), compared

114 or age; sex; smoking status; alcohol intake; SBP; DBP; cholesterol:high-density lipoprotein ratio; di

115 Intensive SBP control was projected to prevent 46 100 (95% CI, 41

116 Intensive SBP lowering increased risk for incident CKD events, but

117 implemented in eligible US adults, intensive SBP treatment could prevent approximately 107 500 deaths

118 year number-needed-to-treat for an intensive SBP goal of 120 mm Hg by applying the treatment benefit

119 nce interval [CI], 1.91-2.48), and intensive SBP treatment was projected to prevent approximately 107

120 To examine the effects of intensive SBP lowering on kidney and cardiovascular outcomes and c

121 erse events incurred if the SPRINT intensive SBP treatment goal were implemented in all eligible US a

122 However, the effects of the intensive SBP intervention on the primary outcome were not influen

123 o evidence that the benefit of the intensive SBP lowering differed by baseline DBP.

124 of deaths prevented per year with intensive SBP control was 34 600 to 179 600.

125 rious adverse events incurred with intensive SBP treatment.

126 isk for cardiovascular disease to intensive (SBP<120 mm Hg) or conventional (SBP<140 mm Hg) treatment

127 a three-gene cluster also encoding a lipase (SBP) and a Nod-like receptor, both of which display the

128 sition by HmuUV-T where the substrate-loaded SBP docks to the nucleotide-free outward-facing conforma

129 Lower SBP at 30 days after TAVR was associated with higher mor

130 Lower SBP treatment levels may result in improved cognition in

131 ater difference between the higher and lower SBP levels in the decrease in cognition; adjusted differ

132 (1 or 2 mg Fe . d(-1)) in infancy have lower SBP at 7 y.

133 uced sodium intake and the DASH diet lowered SBP throughout the range of pre- and stage 1 hypertensio

134 MC consumption significantly lowered SBP (P < 0.05) over a period of 3 h, with peak reduction

135 Patients in the lowest SBP stratum were older, had a higher body mass index, sm

136 Mean SBP and DBP levels were calculated for daytime (10:00 am

137 were black; mean age was 48 years, and mean SBP/diastolic BP was 135/86 mm Hg.

138 ned in covariate-adjusted analyses, the mean SBP in LBW children who had received iron supplementatio

139 Hg, or 150 mm Hg or higher based on the mean SBP level of 2 seated readings.

140 The mean SBP/DBP was 112/69 mm Hg in blacks and 109/68 mm Hg in w

141 (from high to low) was associated with mean SBP differences of -3.20, -8.56, -8.99, and -7.04 mm Hg

142 th the control diet was associated with mean SBP differences of -4.5, -4.3, -4.7, and -10.6 mm Hg, re

143 nance, particularly in positively modulating SBP.

144 resholds for daytime, 24-hour, and nighttime SBP corresponding to a clinic SBP >/=140 mm Hg were 138

145 resholds for daytime, 24-hour, and nighttime SBP were 140 mm Hg, 137 mm Hg, and 133 mm Hg, respective

146 -hour SBP/DBP >/=130/80 mm Hg, and nighttime SBP/DBP >/=120/70 mm Hg) have been derived from European

147 -hour SBP/DBP >/=135/80 mm Hg, and nighttime SBP/DBP >/=130/75 mm Hg, respectively.

148 resholds for daytime, 24-hour, and nighttime SBP/DBP corresponding to clinic SBP/DBP of 140/90 mm Hg

149 resholds for daytime, 24-hour, and nighttime SBP/DBP corresponding to clinic SBP/DBP of 140/90 mm Hg

150 Patients with cirrhosis and nosocomial SBP were randomized to receive meropenem (1 g/8 hours) p

151 n ceftazidime in the treatment of nosocomial SBP (86.7 vs. 25%; P < 0.001).

152 ephalosporins in the treatment of nosocomial SBP.

153 empirical antibiotic treatment of nosocomial SBP.

154 s ceftazidime in the treatment of nosocomial SBP.

155 90-day survival in patients with nosocomial SBP.

156 as DBP (HR, 1.74; 95% CI, 1.21-2.50) but not SBP (HR, 0.82; 95% CI, 0.57-1.18) was associated with CV

157 cholesterol, triglycerides, and DBP, but not SBP, decreased over time (P < 0.05).

158 Mixed models assessed the association of SBP levels with 10-year cognitive trajectories.

159 We found that elevation of SBP levels by 1 mmHg due to our genetic score was associ

160 The adjusted HR of SBP for current PPI users versus nonusers was 1.72 (95%

161 uctions in adults with the highest levels of SBP (>/=150 mm Hg) were striking and reinforce the impor

162 cy of treatment defined by the resolution of SBP after 7 days of treatment.

163 been considered the first-line treatment of SBP.

164 -4.4 mm Hg (-7.2 to -1.6; p=0.0024), office SBP -7.7 mm Hg (-14.0 to -1.5; p=0.0155), and office DBP

165 diet versus the high sodium-control diet on SBP were -5.3, -7.5, -9.7, and -20.8 mm Hg, respectively

166 n blood pressure during sleep opportunities (SBP, +5.6 mmHg; DBP, +1.9 mmHg) and, to a lesser extent,

167 ations between PPIs and development of HE or SBP in patients with cirrhosis with ascites.

168 L1 risk alleles were associated with overall SBP (pcom = 7.0 x 10(-8)) and diastolic blood pressure (

169 38-amino acid streptavidin-binding peptide (SBP) that is appended to the reporter.

170 forming silver 4,4'-bipyridine perchlorate (SBP).

171 y raised blood pressure during wake periods (SBP, +1.6 mmHg; DBP, +1.4 mmHg).

172 o lead to spontaneous bacterial peritonitis (SBP).

173 risk has the potential to guide personalized SBP goals (eg, choosing a traditional goal of 140 or a m

174 etermining greater ICH growth including poor SBP control, dIVH is independently associated with poor

175 disease and normal systolic blood pressure (SBP < 130 mmHg).

176 luded systolic and diastolic blood pressure (SBP and DBP), central pulse pressure (cPP) and flow-medi

177 ne on systolic and diastolic blood pressure (SBP and DBP, respectively) in adults with the use of Men

178 Reduction in systolic blood pressure (SBP reduction) during the treatment of acute decompensat

179 early hypertension [systolic blood pressure (SBP) >/=130 mm Hg, diastolic blood pressure >/=80 mm Hg,

180 .86, OR8%+ = 3.22), systolic blood pressure (SBP) (ORper 10mmHg+ = 1.19), and insulin treatment (ORin

181 Baseline systolic blood pressure (SBP) 140 mm Hg or higher was associated with greater inc

182 hesis that elevated systolic blood pressure (SBP) across its usual spectrum is associated with higher

183 additive model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 t

184 eter Valve) who had systolic blood pressure (SBP) and an echocardiogram obtained 30 days after TAVR.

185 f the trial in both systolic blood pressure (SBP) and diastolic blood pressure (DBP) between the magn

186 emic load (GL) with systolic blood pressure (SBP) and diastolic blood pressure (DBP) in healthy indiv

187 eight ratio (WHtR), systolic blood pressure (SBP) and diastolic blood pressure (DBP).

188 risks, such as high systolic blood pressure (SBP) and high total cholesterol.

189 s of critically low systolic blood pressure (SBP) and/or mean arterial pressure (MAP).

190 m-control diets) on systolic blood pressure (SBP) by baseline BP.

191 by flow cytometry, systolic blood pressure (SBP) by telemetry, and mesentery artery endothelial func

192 bjects (P = 0.040); systolic blood pressure (SBP) did not differ (P = 0.86).

193 ervention Trial), a systolic blood pressure (SBP) goal of <120 mm Hg resulted in lower cardiovascular

194 se mortality with a systolic blood pressure (SBP) goal of <120 versus <140 mm Hg among US adults at h

195 delines recommend a systolic blood pressure (SBP) goal of less than 150 mm Hg for adults aged 60 year

196 reatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncerta

197 shown that elevated systolic blood pressure (SBP) is associated with future onset of type 2 diabetes,

198 risks of intensive systolic blood pressure (SBP) lowering are unclear.

199 CKD) with intensive systolic blood pressure (SBP) lowering is unclear.

200 ents with an office systolic blood pressure (SBP) of 150 mm Hg or greater and less than 180 mm Hg, of

201 >/=20 mm Hg drop in systolic blood pressure (SBP) or >/=10 mm Hg drop in diastolic blood pressure (DB

202 benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other trials, such as Heart Outco

203 ecommended treating systolic blood pressure (SBP) to a target below 150 mm Hg in older adults, wherea

204 The optimal systolic blood pressure (SBP) treatment goal is in question, with SPRINT (Systoli

205 risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest.

206 Low systolic blood pressure (SBP) values are associated with an increased risk of car

207 l deterioration and systolic blood pressure (SBP) with decreased urinary catecholamine compared to di

208 imed at achieving a systolic blood pressure (SBP) within 10% of the reference value (ie, patient's re

209 ctin (sP-selectin), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were assessed.

210 elationship between systolic blood pressure (SBP), calf electromyography (EMG), and resultant center

211 at the age of 7 y, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the prevalence

212 e, male sex, higher systolic blood pressure (SBP), faster heart rate, greater myopia, self-reported g

213 Systolic blood pressure (SBP), heart rate (HR), pathology, and left ventricular m

214 For systolic blood pressure (SBP), nickel (Ni) and sodium (Na) were selected by the a

215 inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion, segmental sclerosis, po

216 us ICH and elevated systolic blood pressure (SBP)-randomly assigned to intensive (<140 mm Hg) or guid

217 biomarkers and low systolic blood pressure (SBP).

218 ons in 24-h BP [for systolic blood pressure (SBP): -3.9 mm Hg; for diastolic blood pressure (DBP): -2

219 with systolic and diastolic blood pressure (SBP/DBP) >/=140/90 mm Hg.

220 bA1c], systolic or diastolic blood pressure [SBP/DBP], total [TC] or HDL-cholesterol).

221 and systolic and diastolic blood pressures (SBP and DBP, respectively)].

222 ram (NSLP) and the School Breakfast Program (SBP) than in nonparticipants.

223 h a high-affinity substrate-binding protein (SBP) to import essential micronutrients.

224 inc by a periplasmic solute-binding protein (SBP).

225 The substrate binding proteins (SBP) of TRAP transporters are the best studied component

226 Periplasmic substrate-binding proteins (SBPs) bind to the specific ligand with high affinity and

227 ting that these novel proteins were putative SBP-AR-interacting proteins in N-AR cells.

228 biochemical associations between recombinant SBP-AR and the ligand-sensitive coatomer protein complex

229 ong-term outcomes of the various recommended SBP levels and to determine if racial differences exist

230 MC intake acutely reduces SBP in men with early hypertension.

231 d urinary albumin excretion without reducing SBP.

232 f the reference value (ie, patient's resting SBP) or standard management strategy of treating SBP les

233 reduction of sVCAM-1, sICAM-1, sP-selectin, SBP, and DBP after 6 wk of hesperidin treatment.

234 third VC-based model using WGS and simulated SBP phenotypes that constrained the beta coefficient for

235 nges in the N-acetylneuraminic acid-specific SBP VcSiaP.

236 sent intact structures for the zinc-specific SBP AztC from the bacterium Paracoccus denitrificans in

237 ceiving treatment for hypertension, a SPRINT SBP level of 120 mm Hg or lower was not associated with

238 andom assignment to an intensive or standard SBP goal (120 or 140 mm Hg, respectively).

239 uctures available for the ligand-bound sugar SBPs, but very few unliganded structures are reported.

240 No structural data are available for sugar SBPs fromPseudomonassp. to date.

241 ry toolbox here with a second reagent, sulfo-SBP (benzophenone).

242 When compared to WT offspring, systolic (SBP), diastolic (DBP) and mean (MAP) BP progressively in

243 Target SBP guidelines have not addressed the potential that bla

244 ly assigned to intensive BP lowering (target SBP <120 mm Hg) and 4078 assigned to standard BP lowerin

245 078 assigned to standard BP lowering (target SBP <140 mm Hg).

246 ent evidence, largely from 1 trial targeting SBP less than 120 mm Hg, that lower BP targets are benef

247 more able to identify future CVD events than SBP in all individuals younger than 50 years.

248 n the absence of ATP the transporter and the SBP tightly bind.

249 interaction between the transporter and the SBP, thus allowing transfer of the substrate from the la

250 vents and all-cause mortality just below the SBP target.

251 tial decrease in 3MSE and DSST scores by the SBP levels, with the greatest decrease in the group with

252 tly (P < 0.001) declined in both groups, the SBP group had significantly lower levels of BDNF (P = 0.

253 The protein is the SBP of VcSiaPQM, a sialic acid TRAP transporter from Vib

254 analysis examined whether the effects of the SBP intervention differed by baseline DBP.

255 te delivery to the cytoplasm, release of the SBP, and resetting of the system.

256 HELLP targets the SBP lipase to the membrane, suggesting a synergy between

257 re level because the J curve aligns with the SBP target.

258 d WHtR were positively associated with their SBP and DBP.

259 The binding of coexpressed streptavidin to SBP causes signal masking, whereas addition of biotin ca

260 When titrating treatment to SBP <140 mm Hg, it may be prudent to ensure that DBP lev

261 higher causal drive in the direction towards SBP and COPr.

262 with the open and closed forms seen in TRAP SBP crystal structures.

263 clusion, these data are consistent with TRAP SBPs undergoing a simple two-state transition from an op

264 or standard management strategy of treating SBP less than 80 mm Hg or lower than 40% from the refere

265 Low on-treatment SBP levels are associated with increased cardiovascular

266 ssessed the association between on-treatment SBP levels, cardiovascular events, and all-cause mortali

267 ooled data consisted of 194 875 on-treatment SBP measurements in 13 946 patients (98.9%).

268 ascular events against the mean on-treatment SBP per treatment group.

269 lesterol, TC:HDL cholesterol, triglycerides, SBP, and DBP; calculated overall effect sizes of change

270 icted outcomes than baseline or time-updated SBP, and was associated with the lowest risk at approxim

271 Our primary exposure variable was SBP and our primary outcome was incident reports of mitr

272 est determinants of both IOPg and IOPcc were SBP (partial R(2): IOPg 2.30%, IOPcc 2.26%), followed by

273 eat of 99 for CAC=0 and 24 for CAC>100, when SBP 120-139mm Hg).

274 ical association between CAC and events when SBP was 160 to 179 mm Hg, irrespective of ASCVD risk lev

275 ly low and varied less among CAC strata when SBP was 160 to 179 mm Hg or when ASCVD risk was >/=15% a

276 Our objective was to determine whether SBP reduction or titration of oral neurohormonal antagon

277 ) were increased compared with those in whom SBP was 120-140 mm Hg during treatment (HR 1 for all out

278 cts of these interventions among adults with SBP >/=160 mm Hg.

279 he number and characteristics of adults with SBP of 120 mm Hg or higher, including SPRINT and HOPE-3

280 CVD risk-reduction measures for adults with SBP/DBP <140/90 mm Hg at high risk for CVD may be warran

281 incident CVD events occur in US adults with SBP/DBP <140/90 mm Hg.

282 steine concentration was not associated with SBP (beta = 0.6 mm Hg for each 1-SD unit increase in log

283 We used 28 genetic variants associated with SBP and evaluated their impact on type 2 diabetes using

284 d on 13 variants exclusively associated with SBP and found a similar increase in type 2 diabetes risk

285 sociation of homocysteine concentration with SBP and DBP was assessed by conventional ordinary least-

286 T) and the lowest decrease in the group with SBP levels of 120 mm Hg or lower (adjusted decrease was

287 ls of 150 mm Hg or higher and the group with SBP levels of 120 mm Hg or lower were -0.05 in white pat

288 with the greatest decrease in the group with SBP levels of 150 mm Hg or higher (adjusted decrease was

289 adjusted differences between the group with SBP levels of 150 mm Hg or higher and the group with SBP

290 ants taking antihypertensive medication with SBP/DBP <140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) were el

291 -Ethnic Study of Atherosclerosis (MESA) with SBP between 120 and 179 mm Hg.

292 1.1) of events occurred in participants with SBP/DBP <140/90 mm Hg; 58.4% (95% CI, 47.7-69.2) and 68.

293 We enrolled 41 drug-naive patients with SBP and 48 with BP-II undergoing 12 weeks of pharmacolog

294 Patients with SBP and BP-II respond similarly to treatment, but SBP pa

295 In 4052 patients with SBP less than 120 mm Hg on treatment, the risk of the co

296 In persons with SBP <160 mm Hg, CAC stratified risk for events.

297 SBP and DBP, jointly suggested that, at Y0, SBP (hazard ratio [HR] per 1-SD increase, 1.32; 95% CI,

298 INT inclusion criteria were age >/=50 years, SBP 130 to 180 mm Hg depending on the number of antihype

299 SPRINT eligibility included age >/=50 years, SBP of 130 to 180 mm Hg (depending on the number of anti

300 Zinc SBPs are characterized by a flexible loop near the high-